MARKER THERAPEUTICS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of GX1 for the last quarter is 1.09 M EUR, and it's 5.32% lower compared to the previous quarter. The net income of Q2 24 is -2.05 M EUR.